AVA-NP-695 / Avammune - LARVOL DELTA

Pharmacologic Inhibition of ENPP1 by AVA-NP-695 Synergizes with DNA Damage Response Inhibitors in Preclinical Models of Osteosarcoma and Ewing Sarcoma (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • ENPP1

Combination of AVA-NP-695 and DDRi demonstrates strong synergy resulting in potent anti-tumor activity in rare pediatric cancers (AACR 2026) - "These findings underscore the therapeutic potential of AVA-NP-695 across hard-to-treat ICB-refractory pediatric cancers such as OS and EWS. AVA-NP-695 exploits ENPP1 inhibition to exert a strong anti-tumor response and obliviates metastasis. Additionally, AVA-NP-695 also demonstrates strong synergy with DDR inhibitors like Olaparib and Ceralasertib in both these cancers."

Clinical • Breast Cancer • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • ENPP1

Exploring the therapeutic benefit of AVA-NP-695 with combination modalities in ICB refractory and rare cancers (AACR 2025) - "The efficacy of AVA-NP-695 was demonstrated in 4T1 Tumor bearing BALB/c mice as monotherapy and in combination with anti-PD-L1, Olaparib and Paclitaxel. The potent anti-tumor efficacy of AVA-NP-695 both as monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 against solids tumors (breast cancer and Osteosarcoma). Our results uncover novel mechanistic vulnerabilities and suggest that treatment with AVA-NP-695 in combination may increase effectiveness in patients, thus preventing local and distant dissemination."

IO biomarker • Breast Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • ENPP1

AVA-NP-695 Demonstrates Strong Anti-Cancer Activity in ICB-Refractory & Rare Cancers (SITC 2025) - "In vivo efficacy was assessed in 4T1 tumor-bearing BALB/c mice, both as monotherapy and with anti-PD-L1, Olaparib (PARP inhibitor), or Paclitaxel. AVA-NP-695 exploits ENPP1 inhibition to exert a strong anti-tumor response and obliviates metastasis. Interestingly, AVA-NP-695 doesn't restrict itself to a single combination modality and demonstrates cancer agnostic features both as monotherapy and also in combination with other existing standard of care treatment such as anti-PD-1 or Paclitaxel or PARP inhibitors."

IO biomarker • Breast Cancer • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • ENPP1

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer. (PubMed, Signal Transduct Target Ther) - "Blockade of ENPP1 using a permeable ENPP1 inhibitor (AVA-NP-695) reduced radioresistance, mechanistically attributed to decreased homologous recombination (HR) resulting in persistent DNA damage, as evidenced by enhanced tail moment and sustained γH2AX formation...Remarkably, combined treatment post-IR reduced spontaneous metastasis and local recurrence, and induced abscopal effects that impacted distant tumor spread in orthotopic tumor models. Thus, these findings position ENPP1 as a critical link between genome integrity and immunosuppression, offering promising translational opportunities for treating local or distant dissemination in TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CTCs • ENPP1 • STING

Healthtech Startup Avammune Bags $12 Mn From Capital 2B, Others (Inc42) - "Healthtech startup Avammune Therapeutics has raised $12 Mn (INR 100 Cr) as a part of its Series A funding round co-led by Capital 2B, Shastra VC and Kotak Alternate Asset Managers’ Life Sciences Fund I. The round also saw participation from IvyCap Ventures, 1Crowd and others. The company plans to use the fresh capital to boost its IP portfolio and support clinical development of its lead candidate AVA-NP-695 (an ENPP1 inhibitor) and preclinical development of other pipeline molecules."

Financing • Breast Cancer • Ewing Sarcoma • Osteosarcoma

Exploring the therapeutic benefit of AVA-NP-695 (ENPP1 inhibitor) and DNA damage inhibition to activation of the immune system in metastatic osteosarcoma (SITC 2024) - "The efficacy of AVA-NP-695 was demonstrated in F420- C57/BL6 mice and K7M2-BALB/c mice as monotherapy and in combination with clinically approved DDR-inhibitors like Olaparib. Conclusions The anti-tumor efficacy of AVA-NP-695 in monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 in pediatrics tumors like Osteosarcoma. Our results uncover novel mechanistic vulnerabilities and suggest that treatment with AVA-NP-695 in combination may increase effectiveness in patients, thus preventing local and distant dissemination."

Metastases • Breast Cancer • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • ENPP1

AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation (SITC 2023) - "The efficacy of AVA-NP-695 was demonstrated in 4T1 Tumor bearing BALB/c mice as monotherapy and in combination with anti-PD-L1, Olaparib and Paclitaxel. Finally, combination of AVA-NP-695 with radiation (Fractionated dose and Targeted Radionuclide) demonstrated substantial tumor growth reduction across various tumor models. Conclusions The potent anti-tumor efficacy of AVA-NP-695 both as monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 against solids tumors, particularly breast cancer."

Clinical • Combination therapy • IO biomarker • Monotherapy • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

AVA-NP-695, a potent and selective ENPP1 inhibitor, abrogates tumor metastasis in 4T1 syngeneic tumor model and demonstrates strong tumor regression when combined with radiation (AACR 2023) - "The efficacy of AVA-NP-695 was depicted in 4T1 Tumor bearing BALB/c mice as monotherapy and in combination with anti-PD-L1, Olaparib and Paclitaxel. The potent anti-tumor efficacy of AVA-NP-695 both as monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 against solids tumors, particularly breast cancer."

Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

AVA-NP-695 Potently and Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model (SITC 2022) - "The efficacy of AVA-NP-695 was depicted in 4T1 Tumor bearing BALB/c mice as monotherapy and in combination with anti-PD-L1, Olaparib and Paclitaxel. Combination group showed significantly delayed recurrence compared to only radiotherapy. Conclusions The potent anti-tumor efficacy of AVA-NP-695 both as monotherapy and combination along with its safety profile provides a strong rationale for the therapeutic potential of AVA-NP-695 against solids tumors, particularly breast cancer."

Preclinical • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model. (PubMed, Molecules) - "Finally, results from the in vivo study showed superior tumor growth inhibition and impact on tumor metastasis of AVA-NP-695 compared to Olaparib and PD-1 in a syngeneic 4T1 breast cancer mouse model. The translation of efficacy from in vitro to in vivo 4T1 tumor model provides a strong rationale for the therapeutic potential of AVA-NP-695 against triple-negative breast cancer (TNBC) as an immunomodulatory and anti-metastatic agent."

Journal • Preclinical • Breast Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor • Triple Negative Breast Cancer • CGAS • PD-1 • STING